| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 7,790 | 3,980 | 3,410 | 6,030 | 8,840 |
| Sales Growth | +95.73% | +16.72% | -43.45% | -31.79% | -9.98% |
| Net Income | -8,400 | -6,970 | -9,530 | -5,480 | -4,640 |
| Net Income Growth | -20.52% | +26.86% | -73.91% | -18.10% | +54.69% |
Casi Pharmaceuticals Inc (CASI)
1.85 x 1 3.52 x 2
Pre-market by (Cboe BZX)
2.20 +0.09 (+4.27%) 03/27/25 [NASDAQ]
1.85 x 1 3.52 x 2
Pre-market 2.20 unch (unch) 16:00 ET
for Thu, Mar 27th, 2025
CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.
Fiscal Year End Date: 12/31